Established by Dr Christopher Thornton, Isca Diagnostics is a University of Exeter spin-out company specialising in point-of-care diagnostics for life-threatening fungal infections of humans.
Isca enables transfer of Dr Thornton’s University R&D in hybridoma technology and monoclonal antibodies to the medical sector, providing the healthcare profession with easy access to highly accurate diagnostic tests for human mycoses.
In 2012, Isca Diagnostics entered into a strategic partnership with OLM Diagnostics, to offer a range of diagnostic tests for opportunistic fungal infections of humans using Isca’s monoclonal antibodies specific to Candida, Aspergillus, Fusarium, Pseudallescheria-Scedosporium complex, Lomentospora (Scedosporium) prolificans and Trichosporon.
Isca as an SME partner
Isca is proud to be a company partner in the EU-funded five-year FP7 project MATHIAS developing novel diagnostic and therapeutic strategies for invasive pulmonary aspergillosis, a devastating disease of immuno-compromised patients. Isca’s role in the development of humanized, F(ab), and scFv versions of its patented monoclonal antibody JF5, means that state-of-the-art molecular imaging of Aspergillus lung infections will be available in the hospital setting, in the near future.